Assessing the degree or patterns of spatial intratumoral TILs heterogeneity might also be an option for a more detailed description of the immune response status of the tumor, as recently suggested for ER/PgR negative breast cancer [16]. The gene discussed is ESR1; the disease is breast cancer.